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n INTRODUCTION
A ccording to the World Health Organiza-tion (WHO) tuberculosis (TB) remains amajor health problem with one third of
the world population infected and 8,6 million
new cases in 2012 [1]. Oral tuberculosis is a rare
entity that accounts for 0,1-5% of all TB infec-
tions. Mycobacterium tuberculosis can infect all
parts of the mouth such as the gingiva, soft and
hard palate, lips, maxilla, mandible and the
tongue. The tongue is the most common site of
oral TB. 
Lesions commonly appear as a single, swollen
non-healing ulcer that often resembles malig-
nant neoplasms. Tuberculosis is rarely consid-
ered in differential diagnosis of oral ulcers and
often diagnosis is made by pathological exami-
nation [2]. In recent years rheumatoid arthritis
(RA) treatment takes advantage of biological
drugs that inhibit Tumor Necrosis Factor alpha
(TNFα). TNFα inhibitors include monoclonal
antibodies like infliximab (IFN) or adalimumab
(ADA), and the soluble TNF receptor-Fc fusion
protein etanercept (ETA). This therapy is asso-
ciated with an increased risk of active TB, espe-
cially due to latent tuberculosis (LTB) reactiva-
tion [3]. 
Risk of tuberculosis is higher for monoclonal an-
tibodies than ETA [4]. Therefore, RA guidelines
introduced TB screening by TST and, more re-
cently, by in vitro Interferon-γ release assays
(IGRAs) before treatment with anti-TNFα
agents to prevent LTB reactivation [5, 6]. We
describe a case of a RA patient treated for long
time with MTX and ADA suffering from a non-
healing ulcer of the tongue.
n CASE PRESENTATION
A 71-year-old woman was admitted to our di-
vision in March 2011 with two months history
of ulcerated, non-healing lesion of the tongue.
The patient suffered from RA for 20 years and
she was on ADA and MTX treatment for the
last 6 years. Previously she was treated with
prednisone, INF and ETA. 
Pretreatment TST was reported to be negative
and no IGRAs were performed. The patient had
no history of BCG vaccination. She reported as-
thenia, pharyngodinia, dysphagia, low grade
fever and night sweats in the last 3 months. On
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physical examination, the patient had an ulcer-
ated swelling on the left border of the base of
the tongue, cervical lymphadenopathy and ul-
nar deviation of metacarpophalangeal joints bi-
laterally. 
Thoracic examination was normal. Cervical CT
scan revealed a reduced lumen of the pharynx
with an infiltrated left wall, left cervical 
lymphadenopathy and left pyriform sinus
obliteration. Chest CT showed mediastinal cal-
cified lymphadenopathies (Figure 1). An initial
diagnosis of squamous cell carcinoma of the
tongue was pointed out. Biopsy of the lesion
showed chronic inflammatory changes, numer-
ous epithelioid and Langhan’s giant cells gran-
ulomata without malignant cells (Figure 2). 
Routine blood tests revealed mild anemia (Hb
11,4 g/dl), normal white blood cells count, 
erythrocyte sedimentation rate 73 mm/hr, C-
reactive protein 56 mg/L (reference <5 mg/L).
Serologic tests for HIV, Epstein Barr Virus, Cy-
tomegalovirus, Herpes simplex virus, Brucella
and Toxoplasma gondii were all negative. TST
was strongly positive (35x35 mm) and T-SPOT-
TB test was also reactive. Biopsy specimens
were negative for acid-fast bacilli but mycobac-
terial culture was positive. Afterwards MTX
and ADA were discontinued and the patient
was treated for 2 months with isoniazid 300 mg
per day, rifampicin 600 mg per day, ethambutol
1200 mg per day and pyrazinamide 1500 mg
per day and then received isoniazid and ri-
fampicin at the same dose for other 7 months. 
Three months after discontinuation of RA ther-
apy the patient presented polyarticular synovi-
tis with severe functional impairment. The pa-
tient reintroduced MTX and received rituximab
with functional improvement. Six months later,
the ulcer was completely healed and cervical
lymphadenopathies were reduced in number
and size.
Figure 1 - a) Neck CT show the infiltration of the hy-
popharynx wall with left pyriform sinus obliteration
(black arrows); b) chest CT show subcarinal calcified
lymph node (black arrowhead).
a b
Figure 2 - Biopsy specimen show granulomatous in-
flammation with epitelioid cells and giant cells that
causes ulceration of the mucosa.
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n DISCUSSION
We presented a case of tuberculosis of the
tongue in a RA patient treated with MTX and
ADA for 6 years. 
Previously the patient received high dose of
prednisone, INF and subsequently ETA. TNFα
is the most important cytokine in the host re-
sponse to TB infection. Particularly TNFα is es-
sential for macrophage activation, inflammato-
ry cell recruitment, granuloma formation and
maintenance of granuloma integrity [7]. 
Although the probability of TB infection is very
low for MTX, this risk is more consistent for
TNFα inhibitors with an increased risk to de-
velop extrapulmonary and disseminate TB dis-
ease [8]. 
In the literature there are only two reports on
oral TB in RA patients treated with ADA and
MTX. In one report the patient developed TB
after 3 months of treatment and no pretreat-
ment TST result was reported. 
As in our case, in the second report TB arose af-
ter a long time of treatment, TST was reported
to be negative pre-therapy and conversed posi-
tive when the patient developed oral TB [9, 10].
Oral TB is a rare entity and may be either pri-
mary or, more often, secondary to pulmonary
TB. Primary oral TB is more common in young
people while secondary form is more common
in adults [11]. 
The tongue is affected most commonly. The in-
tegrity of oral mucosa, the cleaning action of
saliva, the presence of oral saprophytes and
submucosal antibodies presents a natural resis-
tance to Mycobacterium invasion. 
Oral trauma, inflammatory conditions, poor
oral hygiene or tooth extraction may represent
a route of entry for Mycobacterium [2]. Howev-
er, in our case, the patient didn’t report any of
these risk factors. 
Primary oral TB presents mainly as painful
chronic non healing ulcers and are more often
associated with cervical lymphadenopathy [11].
Since 2008 American College of Rheumatology
(ACR) guidelines for the use of TNFα inhibitors
in RA patients put strong attention to the
screening of LTB with an initial TST in all pa-
tients, being considered for therapy with TNFα
inhibitors, regardless of the presence of risk fac-
tors for LTB or BCG vaccination status. Al-
though 2012 ACR revised guidelines indicate
IGRAs as an alternative to TST, it is not still
clarified if these tests are more useful than TST
in RA patients because they are also influenced
by host immunological status. Severely im-
munocompromised or paediatric patients have
high rate of IGRA indeterminate results [12, 13].
However, in recent studies IGRAs seem to be
more specific and more sensitive than TST in
rheumatologic patients [14, 15]. 
In the present case, an initial TST was negative
and later both TST and IGRA were positive.
The risk to develop TB seems to be different
among different TNFα inhibitors. Patients
treated with ADA or INF have a 3 to 4 fold in-
creased risk to develop TB compared with
those treated with ETA. 
These differences seem to be explained by dif-
ferent pharmacokinetics and pharmacodynam-
ics properties. INF and ADA bind TNFα in a
stable manner, their biologic effect is prolonged
and they have proven to induce apoptosis of T
cells whereas ETA biologic effect is reversible
and has no cytotoxic effects. 
The mean time to TB diagnosis from the start of
TNFα inhibitors is relatively short, which sug-
gests reactivation of LTB [3]. However, as in
our patient, TB may occur after years of treat-
ment with ADA. 
Annual testing for TB is recommended only in
patients who have a high rate of TB exposure
and it was not performed in our patient because
she was considered a low risk patient. Ritux-
imab is a chimeric monoclonal antibody that
targets CD20 positive B cells. 
It was recommended in RA patients with TNF
inhibitors inadequate response or adverse
events. Rituximab seems to be safe in RA pa-
tients who have an elevate risk of TB and it may
be a valid choice in such patients [6, 16].
Keywords: oral tuberculosis, rheumatoid arthri-
tis, adalimumab, metotrexate, IGRA.
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In recent years Tumor Necrosis Factor alpha 
(TNFα) inhibitors have been highly effective in
treating rheumatoid arthritis (RA). However, pa-
tients receiving these inhibitors have an increased
risk of developing tuberculosis (TB). We describe a
rare case of tuberculosis of the tongue in an RA pa-
tient treated with methotrexate (MTX) and the TN-
Fα inhibitor adalimumab (ADA) for the previous
six years. 
Pre-treatment tuberculin skin test (TST) was nega-
tive. The patient was admitted to our division
complaining of a sore throat for months. Clinical
examination revealed a swollen non-healing ulcer
at the base of the tongue, which was suspected to
be a squamous cell carcinoma. Histopathological
assessment unexpectedly revealed a chronic gran-
ulomatous inflammation compatible with tubercu-
losis. TST was strongly positive and the T-Spot-TB
test was also reactive. 
MTX and ADA were discontinued and the patient
received antituberculous treatment with complete
healing of the lesion. 
After three months our patient had a worsening
RA that was treated with MTX and rituximab with
no TB-related adverse events. This case highlights
the importance of considering tuberculosis in the
differential diagnosis of ulcerative lesions of the
oral cavity, especially in immunocompromised pa-
tients treated with TNFα inhibitors. Rituximab can
be a valid alternative therapy in such patients.
SUMMARY
Negli ultimi anni gli inibitori del Tumor Necrosis
Factor alpha (TNFα) si sono dimostrati molto efficaci
nel trattamento dell’artrite reumatoide (AR). Tuttavia i
pazienti trattati con questi inibitori hanno un aumenta-
to rischio di sviluppare la tubercolosi (TB). Qui presen-
tiamo un raro caso di tubercolosi della lingua in una pa-
ziente affetta da AR trattata negli ultimi 6 anni con me-
totrexate (MTX) e l’inibitore del TNFα adalimumab
(ADA). Il test cutaneo alla tubercolina (TST) prima del
trattamento era negativo. La paziente è giunta alla no-
stra osservazione poiché lamentava mal di gola da alcu-
ni mesi. L’esame obiettivo ha rivelato una tumefazione
ulcerata alla base della lingua che si sospettava essere
un carcinoma squamoso. Inaspettatamente, l’esame
istologico ha mostrato una flogosi granulomatosa croni-
ca compatibile con infezione tubercolare. Adesso il TST
risultava fortemente positivo ed il T-Spot-TB era reatti-
vo. MTX ed ADA sono stati sospesi e la paziente ha co-
minciato il trattamento antitubercolare, con completa
guarigione della lesione. Dopo tre mesi la paziente ha
presentato un peggioramento dell’AR trattato con MTX
e rituximab in assenza di eventi avversi correlabili alla
TB. Questo caso clinico sottolinea l’importanza di con-
siderare la tubercolosi nella diagnosi differenziale delle
lesioni ulcerate del cavo orale, in modo particolare nei
pazienti immunodepressi trattati con inibitori del
TNFα. Il rituximab potrebbe essere una valida alterna-
tiva per il trattamento di tali pazienti.
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